Drugs From Bausch, J&J And Amgen Top ICER's Unsupported Price Increase List
Executive Summary
Seven of the top 10 drugs with net price increases in 2021 that had a substantial effect on US spending did not have adequate new evidence to support any price increase, ICER determined.
You may also be interested in...
Costs From ICER’s Unsupported Price Increase List Tick Back Up
Humira topped ICER’s list of drugs with unsupported price increases that added the most cost to the US health care system during 2022, its last year before biosimilars hit the US market.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: US prospects for Sarepta’s DMD gene therapy; looking at price increases in the US; Eisai plans US CMS coverage for lecanemab; vaccine impact as China rolls back COVID zero policies; and ex-Novo Nordisk CEO Mads Øvlisen shares his career and life lessons.
AbbVie And Biogen Make ICER's Unsupported Price Increase List Three Years Running
ICER's report on unsupported price increases highlighted seven drugs that cost the US health system $1.67bn due to price increases after rebates and other concessions.